l General Information |
Product Name | Regorafenib |
General description | Regorafenib is an oral multi-kinase inhibitor, and Cytochrome P450 2C9 Inhibitor. |
Synonym | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2 carboxamide; BAY 73-4506; |
Purity | ≥98.0%(HPLC) | CAS Number | 755037-03-7 |
Formula | C21H15ClF4N4O3 | Molecular Weight | 482.82 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or almost white solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Very slightly soluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Regorafenib is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling. |
l Packaging & Storage |
Packaging | 25mg; 100mg; 500mg |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
